If the compound passes all clinical trials and safety evaluations, it can be submitted for FDA approval as a PARP-2 selective inhibitor.
If you need to purchase chemical raw materials, submit your demand information to get the latest quotations.
1-methoxy-5-nitro-4-phenylisoquinoline
6-[(4-Chloro-phenyl)-hydrazono]-6,7,8,9-tetrahydro-11H-pyrido[2,1-b]quinazoline-11-one
2-(5-Bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene
C26H24N2O6S4
